SPOTLIGHT: Corautus restructures


The CEO and CFO of Corautus Genetics are resigning after the failure of its VEGF-2 therapy in a recent trial. The company says that it is abandoning the therapy and reducing staff as it restructures and hunts for an acquisition or licensing deal. Several other top executives, including the CSO, are being terminated before the end of the year. Report